SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* GIMV NV (Last) (First) (Middle) KAREL OOMSSTRAAT 34 (Street) ANTWERP C9 2018 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Raptor Pharmaceutical Corp [ RPTD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) X Other (specify below) Former 10% owner
	3. Date of Earliest Transaction (Month/Day/Year) 09/17/2009
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	09/17/2009		S		54,022	D	$0.2703(1)	1,490,381	I	See footnote(2)
Common stock	09/17/2009		S		6,778	D	$0.2703(1)	186,998	I	See footnote(3)
Common stock	09/17/2009		S		16,710	D	$0.2703(1)	460,994	I	See footnote(4)
Common stock	09/18/2009		S		244,699	D	$0.2639(5)	1,245,682	I	See footnote(2)
Common stock	09/18/2009		S		30,702	D	$0.2639(5)	156,296	I	See footnote(3)
Common stock	09/18/2009		S		75,689	D	$0.2639(5)	385,306	I	See footnote(4)
Common stock	09/21/2009		S		137,715	D	$0.2502(6)	1,108,507	I	See footnote(2)
Common stock	09/21/2009		S		17,211	D	$0.2502(6)	139,084	I	See footnote(3)
Common stock	09/21/2009		S		42,430	D	$0.2502(6)	342,876	I	See footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person* GIMV NV (Last) (First) (Middle) KAREL OOMSSTRAAT 34 (Street) ANTWERP C9 2018 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director 10% Owner Officer (give title below) X Other (specify below) Former 10% owner

1. Name and Address of Reporting Person* ADVIESBEHEER GIMV LIFE SCIENCES NV (Last) (First) (Middle) KAREL OOMSSTRAAT 34 (Street) ANTWERP C9 2018 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director 10% Owner Officer (give title below) X Other (specify below) Former 10% owner

1. Name and Address of Reporting Person* Biotech Fonds Vlaanderen NV (Last) (First) (Middle) KAREL OOMSSTRAAT 34 (Street) ANTWERP C9 2018 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director 10% Owner Officer (give title below) X Other (specify below) Former 10% owner

Explanation of Responses:

1. Price reflected is the weighted-average sale price for the Torreypines Therapeutics shares sold. The range of sale prices for the transactions reported was $0.2700 to $0.2770 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each seperate price.

2. The reported securities are directly held by Gimv NV. The reporting person on this Form 4 disclaims beneficial ownership of the reported securities except to the extent of his pecuniary intrest herein.

3. The reported securities are directly held by Adviesbeheer Gimv Life Sciences NV. The reporting person on this Form 4 disclaims beneficial ownership of the reported securities except to the extent of his pecuniary intrest herein.

4. The reported securities are directly held by Biotech Fonds Vlaanderen NV. The reporting person on this Form 4 disclaims beneficial ownership of the reported securities except to the extent of his pecuniary intrest herein.

5. Price reflected is the weighted-average sale price for the Torreypines Therapeutics shares sold. The range of sale prices for the transactions reported was $0.2600 to $0.2800 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each seperate price.

6. Price reflected is the weighted-average sale price for the Torreypines Therapeutics shares sold. The range of sale prices for the transactions reported was $0.2500 to $0.2550 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each seperate price.

Remarks:

This report is filed jointly by Gimv NV, Adviesbeheer Gimv Life Sciences NV, and Biotech Fonds Vlaanderen NV, as members of a Section 13(d) "Group". All reported sold securities are Torreypines Therapeutics Inc. shares that are sold before the merger with Raptor Pharmaceuticals Corp.

	Koen Dejonckheere as CEO of Gimv NV	10/01/2009
	Patrick Van Beneden as EVP of Gimv NV	10/01/2009
	Koen Dejonckheere as director of Adviesbeheer Gimv Life Sciences NV	10/01/2009
	Patrick Van Beneden as director of Adviesbeheer Gimv Life Sciences NV	10/01/2009
	Koen Dejonckheere as director of Biotech Fonds Vlaanderen NV	10/01/2009
	Patrick Van Beneden as director of Biotech Fonds Vlaanderen NV	10/01/2009
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.